Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
\- Patients with clinical features consistent with erythrodermic CTCL at initial diagnosis.
Confirmed SS (previously diagnosed), followed at Saint Louis hospital participating center with all the following criteria:
1. Stage T4 erythroderma (stage (erythrodermia ≥ 80% of total body area)
2. The presence of an identical T-cell clone evidenced in blood and skin
3. B2 blood staging at initial diagnosis
You may not be if
Other progressive neoplastic disease
Progressive psychotic disease
Patient under guardianship or curatorship
Patients with state medical aid
Refusal to participate
Clareo Health | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
